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Patient Presentation and History
An 86-year-old man arrived by ambulance at the emergen-
cy department (ED) at 7:15 P.M. with shortness of breath,
wheezing, and sweating. The history obtained of his present
illness was brief due to the patient’s extreme dyspnea. He had
missed his dialysis appointment the previous day, and he 
complained of worsening shortness of breath that morning. En
route he received nebulized albuterol and was on 100% O2 by
nonrebreather mask. The patient had suffered a myocardial 
infarction approximately 7 years previously. He had also un-
dergone two cardiac catheterizations documenting extensive
coronary artery disease (CAD), resulting in angioplasty with
subsequent stent placement. In addition, he had a history of
congestive heart failure (CHF) and hypertension that precipi-
tated end-stage renal failure requiring hemodialysis. He also
had chronic obstructive pulmonary disease (COPD) and was
on home O2 at 2 l/min. His medications were as follows: enal-
april 40 mg/day, clonidine 0.1 mg t.i.d., isosorbide dinatrate 
25 mg/day, atenolol 25 mg/day, salmeterol 2 puffs b.i.d., fluti-
casone 2 puffs b.i.d., albuterol p.r.n., lansoprazole 15 mg/day,
calcium acetate 665 mg t.i.d., and Nephrocaps 1/day. 
Examination
Vital signs were temperature 37.6°C, heart rate 110 beats/
min, respiratory rate 34 breaths/min, blood pressure 200/86
mmHg, SO2 91% on 100% FIO2.
The patient was a well-developed, well-nourished Caucas-
ian male in severe respiratory distress. He was seated in a tri-
pod position, diaphoretic, anxious, and using accessory mus-
cles. Additional observations included the following:
• Neck: neck veins distended
• Heart: S1S2, tachycardic rate, grade II systolic murmur of
greatest intensity at the left lower sternal border
• Lungs: Rapid shallow breathing, scattered wheezing, au-
dible diffuse rales bilaterally
• Abdomen: nontender
• Extremities: warm, 2+ pitting edema
• Neurologic exam: nonfocal.
Physiologically, this patient’s presentation is consistent
with a warm and wet profile (Fig. 1). More than 80% of pa-
tients presenting to the ED with acutely decompensated heart
failure (ADHF) have clinical congestion (i.e., are classified
as being wet) and, if right heart catheterization were per-
formed, would show elevated pulmonary capillary wedge
pressure (PCWP).1 These patients may have adequate (wet-
warm) or reduced (wet-cold) perfusion, with the majority
showing elevation in systemic vascular resistance (SVR).
Clinical indicators of congestion in the assessment of patients
with HF include a recent history of orthopnea and/or evi-
dence on physical examination of jugular venous distention,
hepatojugular reflux, ascites, peripheral edema, leftward ra-
diation of the pulmonic heart sound, or a square wave blood
pressure response to the Valsalva maneuver. 
Initial Emergency Department Course
Non-invasive ventilation was immediately started using bi-
lateral positive airway pressure (BiPAP) with an inspiratory
pressure of 12 mmHg and a base pressure of 5 mmHg. He was
also given an intravenous (IV) nesiritide 2 mcg/kg bolus, fol-
lowed by an infusion of 0.01 mcg/kg/min. Ancillary studies
were as follows:
• Chest x-ray (Fig. 2): cardiomegaly, Kerley B lines, pul-
monary congestion consistent with CHF
• Electrocardiogram: sinus tachycardia at 110 beats/min, bi-
fascicular heart block, no acute ST-T wave changes
• Arterial blood gases: 
o Initial: pH = 7.24, PaO2 = 73 mmHg, PaCO2 = 66
mmHg, SO2 = 91.6%
o 10 P.M.: pH = 7.30, PaO2 = 75 mmHg, PaCO2 = 50
mmHg, SO2 = 92.3%
• Serum laboratory values: Na = 139 mEq/l, K = 5.1 mEq/l,
Cl = 98 mEq/l, HCO3 = 25 mEq/l, blood urea nitro-
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gen = 57 mg/dl, creatinine = 7.8 mg/dl, glucose = 340 mg/dl,
troponin = 0.09 ng/ml.
Subsequent Course
The patient began to show signs of improvement within
minutes of starting BiPAP and nesiritide therapy, as evidenced
by improvement in oxygen saturation (to 98%), a decrease in
respiratory rate (to 22 breaths/min), and improvement upon
repeat arterial blood gas analysis. He was weaned off the
BiPAP to 3 l/min of O2 by nasal cannula while in the ED. After
4 h of ED management, he was transferred to the telemetry
unit in stable condition. He had an uneventful evening free of
dyspnea, chest pain, or arrhythmias and underwent routine
dialysis the following morning.
Discussion
Management of CHF presents unique challenges in patients
with renal failure (RF) who are dialysis dependent.2 Patients
with RF may have elevated B-type natriuretic peptide levels in
the absence of HF; thus, the assay is less useful in this popula-
tion. With patients with RF who have either a relative or abso-
lute resistance to diuretic therapy, medication side effects of
drugs used to treat CHF are of greater concern. The risk of
thiocyanate toxicity with the use of nitroprusside is increased
in patients with RF. In addition, there is a greater than average
risk of arrhythmias with the use of inotropes and digoxin due
to preexisting electrolyte disturbances. Urgent or emergent
dialysis for the management of CHF is accompanied by logis-
tical constraints as well as expense. Finally, the need for me-
chanical ventilation or titration of medication drips requires
admission to the intensive care unit.
Natriuretic peptides such as A-type and B-type (BNP) 
enhance the effects of loop diuretics in patients without renal
impairment. Nesiritide, the recombinant form of BNP, does
not depend on renal clearance, and the balanced vasodilatory
effects of nesiritide make it useful in patients with CHF and
concomitant RF. Nesiritide-treated patients with RF demon-
strate reductions in PCWP and dyspnea similar to those in pa-
tients without RF.3 Similarly, the incidence of hypotension or
arrhythmias does not increase with nesiritide use in the pres-
ence of RF.3 Data from The ADHERE® Registry show that IV
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FIG. 1 Rapid clinical assessment of hemodynamic profiles (wet-
warm focus). PCWP = pulmonary capillary wedge pressure, CI = car-
diac index, SVR = systemic vascular resistance.
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FIG. 2 Initial emergency department chest x-ray performed on this
patient, who presented with signs and symptoms characteristic of a
wet and warm profile. Cardiomegaly, Kerley B lines, and pulmonary
congestion consistent with congestive heart failure were noted. 
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FIG. 3 The ADHERE® Registry: Time-to-treatment (left-hand col-
umn) and LOS (right-hand column) for patients started on intra-
venous vasoactive therapy in the emergency department (ED) and
inpatient unit. The top row represents ED; the bottom row represents
inpatient unit.4
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vasoactives, such as nesiritide, started in the ED are associated
with significantly reduced initial treatment times (1.1 h vs.
22.2 h if started in the inpatient unit, p< 0.0001, Fig. 3).4 Early
initiation of IV vasoactives also impacts length of stay (LOS);
ADHERE® data show that those treated in the ED are associ-
ated with a significantly shorter LOS compared with those
treated in the inpatient unit both in the hospital (3.0 vs. 7.0
days, p<0.0001, Fig. 3) and in the intensive and coronary care
units (ICU/CCU) (2.1 vs. 4.5 days, p< 0.0001).4
In this case, the patient received nesiritide within 15 min of
ED presentation and improved rapidly. This point is notewor-
thy because both the timing and choice of initial HF therapy
appear to have a significant impact on a patient’s hospital
course, clinical outcome, and intensity of care required. A final
advantage of nesiritide is its ability to prevent ICU admission
(in favor of a telemetry bed) in many patients with HF who are
stabilized in the ED. As nesiritide does not demonstrate tachy-
phylaxis, further titration and hemodynamic monitoring are
typically unnecessary.
The patient’s rapid and dramatic improvement suggests that
ED initiation of noninvasive ventilation and IV nesiritide
should be considered in patients with RF who present with de-
compensated heart failure.
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